N/A N=25 A Soft Silicone Wound Contact Layer Containing Silver in the Treatment of Skin Grafts in Surgical Burn Patients.
Burn Injury · Skin Graft
Primary: Part A: Number of Participants With Healing — 3; 21; 2; 22 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=33 A Study to Explore the Effects of Azilsartan Compared to Telmisartan on Insulin Resistance of Patients With Essential Hypertension on Type 2 Diabetes Mellitus by HOMA-R
Essential Hypertension Complicated by Type 2 Diabetes Mellitus
Primary: Change in Insulin Resistance Index (HOMA-R) From Baseline at the End of the Treatment Period (Week 12) — -0.23; 0.22 HOMA-R Score
Phase 3 N=26 Evaluation of Long-term Safety, and Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects With Epilepsy
Epilepsy
Primary: Incidence of Treatment Emergent Adverse Events (TEAEs) During Evaluation Period — 78.9; 71.4 percentage of subjects
Phase 1 N=26 A Study to Determine the Safety, Tolerability, Pharmacokinetics and Dynamic Effects of Different Doses of the Study Drug EMD 525797 in Prostate Cancer
Prostate Cancer · Bone Metastases
Primary: Number of Subjects With Dose Limiting Toxicity (DLT) — 0; 0; 0; 0 subjects
Phase 2 N=20 Pharmacological Treatment of Comorbid Alcohol and Marijuana Withdrawal and Dependence
Cannabis Dependence · Alcohol Dependence · Cannabis Use Disorder
Primary: Change From Week 0 in Cannabis Use Using Urinary CN-THCCOOH Levels at Week 8 — 198.3; 55.9 ng/mg
Phase 2 N=12 Acthar in Treatment of Refractory Dermatomyositis and Polymyositis
Dermatomyositis · Polymyositis
Primary: Specific Aim 1: Number of Subjects Meeting IMACS Preliminary Definition of Improvement (DOI). — 7 Participants
Phase 1 N=20 Phase I Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Participants With Colorectal Cancer (MK-0646-016)
Colorectal Cancer
Primary: Number of Dose-limiting Toxicities (DLTs) — 0; 1 DLT
Phase 2 N=16 Biomarkers in Schizophrenia
Schizophrenia · Schizoaffective Disorder
Primary: PANSS Total — 77.9; 80 units on a scale — p=0.02
Phase 2 N=59 BATTLE Program: Erlotinib in Previously Treated Subjects With Advanced NSCLC
Lung Cancer
Primary: 8 Week Progression-Free Survival Rate (i.e. Disease Control Rate) — 20 Participants
N/A N=31 Novel and Scalable Internet Supplemented Weight Loss Treatment in Primary Care
Overweight · Obesity
Primary: Body Weight in Pounds — 207.4 pounds
Phase 2 N=14 RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma
Uveal Melanoma
Primary: Number of Participants With Complete Response (CR) — 13; 0 Participants
Phase 2 N=19 Inhalation SLIT Cisplatin (Liposomal) for the Treatment of Osteosarcoma Metastatic to the Lung
Osteosarcoma Metastatic
Primary: The Study Medication Was to be Considered Effective if the Population Response Rate Was Found to be Greater Than 20% and Individuals Who Demonstrated a CR or PR or Whose…
Phase 2 N=36 Computerized Cognition Testing in Participants With Mild Alzheimer's Disease (AD) Treated With Donepezil (MK-0000-318)
Alzheimer's Disease
Primary: One-card Learning (OCL) Measurement Over 12 Weeks of Treatment — 0.954; 0.942; 0.822; 0.969 Score on a scale
Phase 3 N=222 A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs in Adults With Hepatitis C Virus Infection, Who Are Either Treatment-naive or Treatment-experienced in Brazil
Chronic Hepatitis C Infection
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) — 96.4 percentage of participants
Phase 2 N=27 Safety and Efficacy of Ranibizumab for Diabetic Macular Edema
Diabetic Macular Edema
Primary: Number of Participants With Non-severe Ocular Adverse Events — 9; 5; 4; 3 Participants — p=<0.05